Brain Tumor, Primary Clinical Trial
Official title:
An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 for Refractory Primary Brain Tumors With BRAF Mutation
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation
Status | Recruiting |
Enrollment | 40 |
Est. completion date | May 30, 2024 |
Est. primary completion date | May 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age>=18Y - Good Organ Function - Expected survival time = 3 months - Refractory primary brain tumors with BRAF mutation that have been diagnosed - Unable to receive surgery/radiotherapy, or have treatment failed after surgery/radiotherapy - ECOG score 0-1; Exclusion Criteria: - Previous treatment with BRAF inhibitors or MEK inhibitors - A history of other malignancies within two years, except for cured cervical carcinoma in situ, basal cell carcinoma of the skin, adenocarcinoma in situ of the lung, or tumors that do not require interventional treatment after radical surgery - Severe active infections requiring systemic anti-infective therapy - Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation therapy (except palliative radiation therapy), may be given during the study period. |
Country | Name | City | State |
---|---|---|---|
China | Cancer Hospital Affiliated to Shandong first medical University | Jinan | Shandong |
Lead Sponsor | Collaborator |
---|---|
Shanghai Henlius Biotech |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ORR | Objective response rate(assessed by independent radiological review committee (IRRC) based on the RANO | from first dose to the last patient was followed up for 6 month | |
Secondary | PFS | Progression-free survival(PFS):assessed by IRRC and the investigator based on the RANO | from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),an average of about 1 year | |
Secondary | DOR | Duration of response | from the first occurrence of a documented CR or PR (whichever recorded earlier) to the time of first documented disease progression or death (whichever occurs first),an average of about 1 year | |
Secondary | OS | Overall survival | from the first dose to the time of death due to any cause,an average of about 2 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06057168 -
Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas
|
Phase 3 | |
Recruiting |
NCT04427384 -
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
|
||
Completed |
NCT03323450 -
Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory
|
N/A | |
Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
Completed |
NCT02599142 -
Comparing Immobilisation Shells in Cranial Radiotherapy
|
N/A | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Recruiting |
NCT06282562 -
FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients
|
N/A | |
Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
Completed |
NCT04365647 -
Intra-operative Variation in Size of Brain Tumors After Craniotomy
|
||
Not yet recruiting |
NCT06185686 -
Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
|
||
Withdrawn |
NCT04776980 -
Multimodality MRI and Liquid Biopsy in GBM
|
Early Phase 1 | |
Completed |
NCT03262636 -
Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)
|
Phase 1 | |
Active, not recruiting |
NCT02006407 -
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
|
N/A | |
Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
Recruiting |
NCT05775458 -
Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
|
||
Terminated |
NCT04901806 -
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03373487 -
Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery
|
N/A | |
Not yet recruiting |
NCT06106997 -
Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow
|
N/A | |
Recruiting |
NCT05254197 -
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
|